Skip to main content

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Written by Customer Service on . Posted in Public Companies.

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.

The Nasdaq notification letter has no immediate impact on the listing or trading of the Company’s common stock, which continues to trade on the Nasdaq Capital Market under the symbol “CELU.” Nasdaq has provided the Company with a 60-day period, or until July 28, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the prescribed due date of the Form 10-Q, or until November 16, 2026, to regain compliance.

The Company is actively working to complete and file its Form 10-Q as soon as practicable and expects to return to full compliance with its SEC reporting obligations and Nasdaq Listing Rule 5250(c)(1).

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.

For more information, visit www.celularity.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s compliance with Nasdaq listing requirements, the Company’s ability to file its Form 10-Q, the timing of any such filing, the Company’s ability to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), Nasdaq’s acceptance of any such plan, the Company’s ability to regain compliance within any applicable cure period and the Company’s SEC reporting obligations. These forward-looking statements are based on current beliefs, expectations, and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.